Join Withum and Mintz privacy and cybersecurity professionals for a live, informative session discussing why biotech-startups need to take cybersecurity seriously, understanding the evolving regulatory/legislative landscape of data security and incident response, and more.
Details
Biological and medical information is more valuable than other types of data; health information on the black market is worth 300x that of credit card details. Big Data and Machine Learning have accelerated early-stage/emerging life-science organizations' capabilities of obtaining investor attention – while also making that sector one of the most targeted for cyber criminals. Biotech startups rely on health information collected from research collaborators, internet-connected medical devices, research laboratories and other provider sources to advance their initiatives. Threat actors continue to expose vulnerabilities, successfully hijacking data sources and other repositories – threatening exposure.
In this session, cybersecurity and privacy professionals from Withum and Mintz will cover:
- Why Biotech-Startups need to take cybersecurity seriously (no matter what stage).
- Learn practical steps to help protect intellectual property, ensuring scientific data remains trustworthy.
- Understanding the evolving regulatory/legislative landscape for privacy and data security.
- Incident Response: how to ensure timely recovery, while limiting exposure.
- Regulatory and Notification Obligations: be aware of reporting and notification obligations resulting from an incident.
Agenda
3:30 - 4:00 pm - Registration and networking
4:00 - 4:45 pm - Panel presentation
4:45 - 5:00 pm - Q&A session
5:00 - 5:30 pm - Cocktails and appetizers
5:30 - 6:30 pm - Pop up pitches with Q&A
6:30 - 7:00 pm - Networking
7:00 pm - Program close
REGISTER HERE
When
Wednesday, April 24, 2024
3:30 – 7:00 pm
Where
Mintz
One Financial Center
40th Floor
Boston, MA 02111